Akeso, Inc.
HKSE: 9926.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Baiyong Li
- Employees
- 3,035
- Headquarters
- Zhongshan, China
- IPO year
- 2020
- Market cap
- HK$123.3B
- Website
- https://www.akesobio.com
Loading 9926…
Loading profile data…Frequently asked questions about 9926
What does Akeso, Inc. (9926.HK) do?
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lu...
Where does 9926.HK trade?
Akeso, Inc. (9926.HK) trades on the Hong Kong Stock Exchange.
What sector is 9926.HK in?
Akeso, Inc. (9926.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Akeso, Inc.?
Baiyong Li is the chief executive officer of Akeso, Inc. (9926.HK).
Where is Akeso, Inc. headquartered?
Akeso, Inc. is headquartered in China.
Does 9926.HK pay a dividend?
Akeso, Inc. (9926.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 9926.HK go public?
Akeso, Inc. (9926.HK) completed its initial public offering in 2020.